At IBDENC, we believe in engage, educate and empower. Our IBD Journal Scan is one way we deliver on that promise: by curating key articles from high-impact journals every month, we offer a clear, expert-driven snapshot of what’s new and noteworthy in IBD research. Whether you're a clinician, researcher, or educator, this resource helps you stay on the frontline of cutting-edge science, with older scans archived so you can revisit past insights as well.
IBD Journal Scan
Key articles from high impact journals in last month
SEP-2026
The September 2026 IBD Journal highlights important advances shaping the understanding and management of inflammatory bowel disease. Updated ECCO guidelines provide evidence-based recommendations for the medical treatment of adults with ulcerative colitis, emphasizing individualized and multidisciplinary care. A move beyond drug-class effects highlights the importance of selecting individual therapies based on pharmacology, efficacy, safety, and patient characteristics. New single-cell genetic research provides a detailed map linking IBD genetic risk to specific genes and cell types, offering insights into immune dysfunction and intestinal barrier disruption. Meanwhile, the evolving IBD burden across East and Southeast Asia highlights the transition from accelerating incidence towards compounding prevalence. Finally, updated AGA guidance on Clostridioides difficile infection in IBD provides practical strategies for diagnosis, treatment, prevention of recurrence, and management of IBD therapy during infection.
ECCO Updates Medical Treatment Guidelines for Ulcerative Colitis
The European Crohn’s and Colitis Organisation (ECCO) has updated its guidelines on the medical management of adult ulcerative colitis (UC), incorporating new evidence since the 2022 recommendations. The guidelines use the GRADE methodology alongside expert consensus and newly introduced practice points where evidence remains limited. Treatment recommendations are stratified by disease severity and extent, recognizing that UC can evolve over time and that proximal disease extension may indicate a poorer prognosis. The updated guidance covers therapeutic approaches for mildly-to-moderately and moderately-to-severely active UC, including approved biologics and small molecules, with induction and maintenance dosing summarized. ECCO emphasizes individualized, multidisciplinary care that considers patient preferences, local regulations, healthcare resources, and psychological and nutritional needs.
Moving Beyond Class Effects Towards Precision IBD Therapy
As treatment options for inflammatory bowel disease (IBD) continue to expand, relying solely on broad drug-class effects may overlook important differences between individual therapies. This article highlights the need to move towards drug-level precision, considering each therapy’s pharmacological characteristics, efficacy, safety profile, and suitability for the individual patient. Although drugs within the same class may share mechanisms of action, their clinical performance and patient suitability can differ significantly. A more personalized approach can help clinicians select treatments based on disease characteristics, previous treatment exposure, comorbidities, safety considerations, and patient preferences. Moving beyond class-based decision-making could therefore support more informed therapeutic choices and improve the precision of IBD care as the treatment landscape becomes increasingly complex.
Single-Cell Analysis Reveals How Genetic Risk Drives IBD
A large-scale study has provided new insights into how genetic variation contributes to inflammatory bowel disease (IBD) by linking genetic risk to specific genes and cell types. Researchers analyzed 2.2 million single cells from intestinal biopsies and blood samples of 421 individuals, including 125 with IBD. Cell-type-specific genetic signals were more strongly linked to known IBD risk loci than conventional tissue-level analyses, helping identify potential disease-driving genes. The study highlighted genes such as MAML2, PSEN2 and ZMIZ1 in myeloid cells, suggesting impaired Notch signalling may contribute to intestinal immune dysfunction. It also identified Wnt-regulated genes, including MYC, in intestinal stem and progenitor cells, pointing to impaired epithelial renewal and barrier disruption. These findings provide a detailed genetic map of IBD risk across different cell types.
IBD Burden in East and Southeast Asia Enters a New Phase
Inflammatory bowel disease (IBD) is rapidly evolving across East and Southeast Asia, with several countries moving through a major epidemiological transition. This review traces the 100-year development of IBD in Japan, South Korea, China, Hong Kong, and Malaysia, highlighting how these regions have progressed from disease emergence to accelerating incidence. While many newly industrialised regions remain in stage 2, characterized by rising incidence, some are approaching stage 3, where prevalence begins to compound as more patients live longer with IBD. These changing patterns signal a growing public health challenge and highlight the need for stronger disease surveillance, healthcare planning, and long-term management strategies. The experience of East and Southeast Asia may also provide an important model for other emerging regions likely to experience similar increases in IBD burden.
AGA Provides Practical Guidance for Managing C. difficile Infection in IBD
The American Gastroenterological Association (AGA) has issued practical guidance for managing Clostridioides difficile infection (CDI) in patients with inflammatory bowel disease (IBD), who face higher risks of severe infection and recurrence. The update emphasizes testing for CDI in patients with new or worsening diarrhea, using multistep toxin-based testing, and preferentially treating initial infection with fidaxomicin or vancomycin, while avoiding metronidazole. Importantly, IBD therapy should generally be continued or initiated when clinically necessary during CDI treatment, with corticosteroids considered when required. Persistent symptoms after 48–72 hours should prompt evaluation for active IBD and possible cytomegalovirus infection. For recurrent CDI, microbiome-based therapies are recommended, while probiotics are not advised for prevention.